Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823156 | 0.90 | HDAC1 (0.54) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL1798901 | 0.86 | HDAC1 (0.52) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL3695642 | 0.86 | HDAC1 (0.55) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL580233 | 0.86 | HDAC1 (0.55) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL2595460 | 0.85 | HDAC1 (0.51) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL13617803 | 0.85 | HDAC1 (0.52) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL13708399 | 0.85 | HDAC1 (0.52) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL6540918 | 0.85 | HDAC1 (0.51) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL27540555 | 0.85 | HDAC1 (0.51) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL9295960 | 0.85 | HDAC1 (0.47) | HDAC1HDAC3HDAC2NCOR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| WO-2004002939-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | HDAC1 2194/4885HDAC3 2349/4885HDAC2 1457/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | HDAC1 864/4885HDAC3 1060/4885HDAC2 573/4885 |
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | HDAC1 1357/4885HDAC3 1205/4885HDAC2 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.